bimekizumab


( Last Updated : October 6, 2021)
Generic Name:
bimekizumab
Project Status:
Active
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
UCB Canada Inc.
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0698-000
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openJuly 19, 2021
Call for patient/clinician input closedSeptember 13, 2021
Clarification:

- Patient input submission received from the Canadian Psoriasis Network (CPN) and Canadian Association of Psoriasis Patients (CAPP)

Submission receivedAugust 17, 2021
Submission acceptedAugust 31, 2021
Review initiatedSeptember 01, 2021
Draft CADTH review report(s) provided to sponsor for commentNovember 16, 2021
Deadline for sponsors commentsNovember 25, 2021
CADTH review report(s) and responses to comments provided to sponsorJanuary 14, 2022
Expert committee meeting (initial)January 26, 2022
Draft recommendation issued to sponsorFebruary 07, 2022
To
February 09, 2022
Draft recommendation posted for stakeholder feedback
End of feedback period